Company: SHPH
Filing Date: 2025-05-15
Form Type: 8-K
Source: 0001641172-25-010964
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-15
Form: 8-K
Item: Item 5.07
Chunk 1
---
───────────
  3,176,560      819,085                   182,379  

A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required for approval. Accordingly, Proposal
2 was approved.

Proposal
No. 3: Advisory Vote on Executive Compensation (“ Say on Pay”)

      Votes        Votes      Abstentions/Withheld         Broker  
        For      Against                                Non-Votes  
 ───────────────────────────────────────────────────────────────────
  2,542,575      469,312                    87,730      1,078,407  

   2  

This
vote is advisory, and therefore not binding on the Company, the Compensation Committee, or the Board of Directors. However, the Compensation
Committee will consider the outcome of the vote when considering future executive compensation arrangements.

Proposal
No. 4: Authorization of the Board of Directors to amend the Company’s amended and restated certificate of incorporation to effect
a Reverse Stock Split of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-100.

      Votes        Votes      Abstentions/Withheld  
        For      Against                            
 ────────────────────────────────────────────────────
  3,090,168      864,467                   223,389  

A
majority of the votes cast was required for approval. Accordingly, Proposal 4 was approved.

Proposal
No. 5: The approval of the first amendment to Shuttle Pharmaceuticals Holdings, Inc.’s 2018 Equity Incentive Plan to increase the
amount of shares reserved for issuance by 5,000,000 shares of common stock.

      Votes        Votes      Abstentions/Withheld         Broker  
        For      Against                                Non-Votes  
 ───────────────────────────────────────────────────────────────────
  2,522,161      492,378                    85,078      1,078,407  

A
majority of the shares present in person or by proxy and entitled to vote at the Meeting was required for approval. Accordingly, Proposal
5 was approved.

Proposal
No. 6: The approval of the issuance of more than 19.99% of our common stock upon conversion of certain convertible notes in compliance
with Nasdaq Listing Rule 5635(d).

      Votes        Votes      Abstentions/Withheld         Broker  
        For